MADISON, Wis.–Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View™ Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex™ arrays from Protein Biotechnologies.

“This launch expands the applications of APiX technology to include not only antibody and protein arrays on clear glass slides, but also tumor lysate arrays on porous nitrocellulose surfaces. Now virtually any commercial protein microarray can take advantage of Gentel’s chromogenic detection.”

Alex Vodenlich, Gentel’s President and CEO, said of the product, “This launch expands the applications of APiX technology to include not only antibody and protein arrays on clear glass slides, but also tumor lysate arrays on porous nitrocellulose surfaces. Now virtually any commercial protein microarray can take advantage of Gentel’s chromogenic detection.”

APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the Gentel Proteomics Multi-System. APiX is also compatible with a variety of secondary antibodies such as anti-mouse and anti-rabbit. APiX uses a proprietary gold-catalyzed silver deposition and typically achieves measurably improved sensitivity compared to fluorescence detection.

Phillip Schwartz, President and CEO of Protein Biotechnologies recognized the potential of the Gentel reagents and system for use with Protein Biotechnologies’ SomaPlex™ tumor lysate arrays. “Our customers are looking for a simple, sensitive, and affordable detection method for use with SomaPlex™ arrays. The Gentel Proteomics Multi-System meets this need,” stated Schwartz. “We are excited about how Gentel’s easy-to-use kits and affordable system can help make arrays accessible to whole a new group of users.”

Tumor lysates arrays are a type of reverse phase protein microarray that contains a collection of up to several hundred tumor samples on slide. Antibodies or other probes are applied to the array to detect the abundance of specific protein biomarkers and rapidly measure expression across a large population of tumor samples. Array results are then compared to demographic and relevant clinical disease-specific data on the tumor collection to draw a conclusion.

APiX View detection reagents are compatible with the Gentel Proteomics Multi-System, which provides “scan-to-analysis” functionality for multiplex immunoassays, tumor lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging.

To learn more about the how APiX View detection works with the SomaPlex™ Human Breast Tumor lysate array visit www.apixview.com.

About Gentel Biosciences, Inc.

Gentel’s mission is to deliver cost-effective, easy-to-use and reliable proteomics products and services that enable researchers to perform faster discovery, validation and screening of protein biomarkers. Gentel’s headquarters is located in Madison, Wisconsin.

About Protein Biotechnologies, Inc.

Protein Biotechnologies manufactures and supplies human clinical specimen derivatives, protein and tissues microarray research products and services to pharmaceutical, biotechnology, government and academic institutions worldwide. The company provides high throughput, proteomics solutions to understand the cause of human disease and accelerate discoveries for the diagnosis and treatment of cancer, diabetes, obesity, allergies, neurodegenerative, cardiovascular, inflammatory, and autoimmune disease research. Protein Biotechnologies’ research and development goals are focused on creating innovative solutions for high throughput biomarker screening and molecular fingerprinting of protein and nucleic acids using one of the largest sources of high quality, well characterized clinical specimens in the world.